skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

 

Cancer is still generating the most new pharma industry-derived drug candidates, according to the measure of numbers of novel compounds reported at the recent biannual American Chemical Society (ACS), held in San Francisco, and verified by Citeline’s Pharmaprojects. But, after a summer of intense press coverage on the lack of industry effort to find new anti-infectives, there were also an encouraging number of new molecules in this area presented.

 

 

Amongst highlights in oncology, Genentech reported a pan-Pim kinase inhibitor for the treatment of multiple myeloma ; not to be outdone; Amgen also provided details and a lead structure of its series of their Pim kinase inhibitors:

 

 

Amgen-pim-kinase-inhibitor

 

 

Also, in oncology, a completely new target was reported by Genentech, which is developing a substituted 4-hydroxy-5,6-dihydropyran-2-one which inhibits human lactate dehydrogenase A (LDHA). This is quite a daring concept, due to the high abundance of cellular LDHA, as well as its catalytic site having a highly hydrophilic nature.

 

 

In the infectious diseases area, Actelion gave details of its tetrahydropyran-based topoisomerase inhibitors, in development for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. UK-based Redx Anti-Infectives also provided information on new antibacterials, disclosing a series of small-molecule 3-methoxybenzamide analogs as FtsZ inhibitors for the treatment of drug-resistant staphylococcal infections. In viral infections, hepatitis-C continues to be hot, with Vertex providing insight into its latest projects: a series of HCV NS5A genotype 1a, 1b inhibitors, and a second series of lactam-containing non-nucleoside HCV NS5B inhibitors (lead structure shown below):

 

 

Vertex-HCV-NS5B-inhibitors

 

 

A number of neurological products were also disclosed, with Suven Life Sciences developing early stage 5-HT4 receptor agonists for the treatment of Alzheimer’s disease; Bristol-Myers Squibb working on BMS-955829, a positive allosteric modulator of mGluR5, as a schizophrenia therapy; and Eli Lilly developing metabotropic glutamate 2/3 antagonists for the treatment of depression. In the cardiovascular space, Gilead provided details on its Nav 1.5 sodium channel inhibitor, GS-462808, which is in early stage development for ischaemic heart disease. Additionally, AstraZeneca presented information on AZD-3971, a trioxoisothiazole-based liver receptor X (LXR) agonist, that is aimed at the treatment of atherosclerosis; and Kowa also produced a poster containing a structure on their LXRβ agonist, K-20770-2b, also in development for atherosclerosis.

 

 

Although this is only a small sample of the many products revealed at this conference, it does highlight that such meetings are still key conduits for the dissemination of information on novel compounds and structural classes for the treatment of a variety of conditions.

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問合せの際は下記メールアドレスまたは各営業スタッフまでご連絡下さいますようご協力をお願い申し上げます。

インフォーマインテリジェンス合同会社
ファーマインテリジェンス
inquiry.jp@informa.com

*Omdia(ICT産業の情報)に関するお問い合わせはこちら
Contact_OmdiaJapan@omdia.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。